Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data BioAtla, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.3
Research and development
25.9
19.9
58.3
79.3
104
63.1
43.6
General and administrative
7.55
10.6
38.4
28.8
26
21.8
17.7
Operating expenses
33.5
30.5
96.7
108
130
84.9
61.3
Operating income
-28.3
-30.1
-96.4
-108
-130
-73.9
-59.3
Interest expense
1.63
1.39
0
0
Interest income
0.13
0.1
0.35
1.65
6.31
3.37
0.84
Other non-operating income
-1.59
-5.75
1.04
1.66
6.23
4.17
-0.3
Income tax
0
0
0
0
0
0
Net income to minority interests
-0.06
0
0
Net income
-29.9
-35.9
-95.4
-106
-123
-69.8
-59.6
EBITDA
-27.4
-29.1
-95.1
-107
-128
-73
-58.9
EPS, basic
-3.19
-2.76
-2.74
-2.58
-1.44
-1.01
EPS, diluted
-3.19
-2.76
-2.74
-2.58
-1.44
-1.01
Shares, basic (weighted)
8.43
34.6
38.9
47.8
48.6
58.8
Shares, diluted (weighted)
8.43
34.6
38.9
47.8
48.6
58.8
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
3.7
239
245
216
111
49
7.12
Receivables
0
Other current assets
2.08
2.31
4.92
4.94
2.19
0.9
Total current assets
241
247
220
116
51.2
8.01
Property, plant and equipment
4.1
3.68
2.73
1.6
0.68
0.12
Lease right-of-use assets
0
3.3
2.42
1.5
0.51
5.53
Other non-current assets
0.15
0.15
0.15
0.15
0
0.16
Total assets
245
254
226
120
52.4
13.8
Accounts payable
2.46
1.18
4.23
3.82
1.9
8.19
Deferred revenue
19.8
0
Total current liabilities
32.3
19.8
23.1
28.3
14.5
21.9
Lease liabilities
0
3.98
2.46
0.84
0
4.77
Total liabilities
35
43.6
45.4
49
38.2
50
Paid-in capital
301
397
473
487
500
509
Retained earnings
-90.9
-186
-293
-416
-486
-546
Shareholders' equity
-56
210
211
180
70.7
14.3
-36.2
Total equity
-56
210
211
180
70.7
14.3
-36.2
Total liabilities and equity
245
254
226
120
52.4
13.8
Shares outstanding
32.2
35.8
46.3
48.1
58.1
1.27
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-29.9
-35.9
-95.4
-106
-123
-69.8
-59.6
Depreciation and amortization
0.86
1.01
1.33
1.2
1.22
0.93
0.37
Stock-based compensation
0
3.02
25.1
14.6
13.5
8.92
5.43
Deferred income tax
0
Change in payables
3.22
-1.66
7.99
3.41
5.28
-13.5
2.8
Cash from operations
-9.65
-36.3
-62.2
-90.4
-104
-71.9
-48.2
Cash from investing
-1.51
-0.59
-0.92
-0.27
-0.1
0
Debt issued
4
2.75
0
Stock issued
0
0
71
61.7
0
9.22
0
Cash from financing
4
272
69.5
61.2
0.08
9.51
6.28
Net change in cash
-7.16
235
6.37
-29.5
-104
-62.4
-41.9
Income taxes paid
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.48 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-330.9%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-353.7%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-73.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-60.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-43.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
21.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
14.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
47.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.20x
Current assets / current liabilities.
Quick ratio
0.17x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.07x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$14.13
Cash from operations / diluted weighted shares.
Book value per share
-$21.79
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-1,276.0%
Net income / market cap (the inverse of P/E).
Was BioAtla, Inc. profitable in fiscal 2025?
No. It reported a net loss of $59.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.